亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Abstract 5151: Nanoliposomal irinotecan (nal-IRI, MM-398) has greater anti-tumor activity than topotecan and irinotecan in mouse models of small cell lung cancer

伊立替康 拓扑替康 医学 喜树碱 药理学 活性代谢物 序号38 拓扑异构酶 药代动力学 癌症 内科学 化疗 化学 生物化学 结直肠癌 有机化学
作者
Shannon C. Leonard,Daniel F. Gaddy,Helen Lee,Stephan G. Klinz,Jonathan B. Fitzgerald,Bart S. Hendriks
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:77 (13_Supplement): 5151-5151
标识
DOI:10.1158/1538-7445.am2017-5151
摘要

Abstract Nal-IRI, a liposomal formulation of irinotecan, is designed for extended circulation relative to non-liposomal irinotecan and to exploit leaky tumor vasculature for enhanced drug delivery to tumors. Following tumor deposition, nal-IRI is taken up by phagocytic cells followed by irinotecan release and conversion to its active metabolite, SN-38. Sustained inhibition of topoisomerase 1 (TOP1) by extended SN-38 exposure is hypothesized to enable superior anti-tumor activity compared to traditional TOP1 inhibitors. Topotecan, another TOP1 inhibitor, is an approved second-line treatment option for small cell lung cancer (SCLC). Here, we evaluate the anti-tumor activity of nal-IRI compared to irinotecan and topotecan in preclinical models of SCLC including those that have been pre-treated with therapeutics used clinically to treat SCLC. Anti-tumor activity of nal-IRI, irinotecan, or topotecan was evaluated based on tumor volume assessments in DMS-53, DMS-114 and NCI-H1048 subcutaneous xenograft models in NOD-SCID mice, as well as in a patient-derived xenograft (PDX) model in nu/nu mice. To approximate clinical dosing: Nal-IRI was dosed at 16 mg/kg (irinotecan HCl basis), q1w, equivalent to a proposed clinical dose of 90 mg/m2 free base, q2w; irinotecan was dosed at 33 mg/kg q1w, equivalent to a clinical dose of 180 mg/m2 q2w; and topotecan was dosed at 0.83 mg/kg/week, day 1-2 every 7 days, which approximates a clinical dose intensity of 1.5 mg/m2 (days 1-5 every 21 days). Additionally, the activity of these agents was evaluated after tumors progressed following prior treatment with either topotecan, irinotecan or the combination of weekly carboplatin (30 mg/kg) plus etoposide (25 mg/kg), a standard first line regimen. Nal-IRI demonstrated anti-tumor activity in xenograft models of SCLC at clinically relevant dose levels, and resulted in complete or partial responses in DMS-53, DMS-114, NCI-H1048 and a PDX model in comparison with irinotecan or topotecan, which each had limited tumor growth control. Furthermore, Nal-IRI demonstrated anti-tumor activity in tumors that progressed following treatment with topotecan, and demonstrated significantly greater anti-tumor activity than both topotecan (p<0.0001) and irinotecan (p<0.0001) in NCI-H1048 tumors (8/8 complete responses) that had progressed on prior carboplatin plus etoposide treatment. These results support the further clinical development of nal-IRI versus IV topotecan in patients with SCLC that progressed on or after prior platinum containing therapy. Citation Format: Shannon C. Leonard, Daniel Gaddy, Helen Lee, Stephan Klinz, Jonathan Fitzgerald, Bart Hendriks. Nanoliposomal irinotecan (nal-IRI, MM-398) has greater anti-tumor activity than topotecan and irinotecan in mouse models of small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5151. doi:10.1158/1538-7445.AM2017-5151

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yyq97完成签到,获得积分10
27秒前
胖小羊完成签到 ,获得积分10
48秒前
量子星尘发布了新的文献求助10
1分钟前
1分钟前
zsmj23完成签到 ,获得积分0
1分钟前
李爱国应助杜阳辉采纳,获得10
2分钟前
量子星尘发布了新的文献求助10
2分钟前
3分钟前
3分钟前
量子星尘发布了新的文献求助10
4分钟前
朴素的无招完成签到 ,获得积分10
4分钟前
4分钟前
5分钟前
量子星尘发布了新的文献求助10
6分钟前
Libgenxxxx完成签到,获得积分10
6分钟前
感动白开水完成签到,获得积分10
6分钟前
科研通AI2S应助科研通管家采纳,获得10
7分钟前
传奇3应助科研通管家采纳,获得10
7分钟前
量子星尘发布了新的文献求助10
7分钟前
叁月二完成签到 ,获得积分10
8分钟前
mama完成签到 ,获得积分10
8分钟前
111完成签到 ,获得积分10
8分钟前
糊涂的青烟完成签到 ,获得积分10
8分钟前
hongtao完成签到 ,获得积分10
8分钟前
缥缈的幻雪完成签到 ,获得积分10
8分钟前
9分钟前
量子星尘发布了新的文献求助10
9分钟前
无花果应助科研通管家采纳,获得10
9分钟前
Jasper应助科研通管家采纳,获得10
9分钟前
10分钟前
10分钟前
一一完成签到 ,获得积分10
10分钟前
桥西小河完成签到 ,获得积分10
10分钟前
量子星尘发布了新的文献求助10
10分钟前
10分钟前
10分钟前
10分钟前
caibaozi完成签到,获得积分10
11分钟前
GingerF应助冷静冰枫采纳,获得100
11分钟前
11分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 330
Deconstructing Syntactic Theory 300
Aktuelle Entwicklungen in der linguistischen Forschung 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3985932
求助须知:如何正确求助?哪些是违规求助? 3528724
关于积分的说明 11240823
捐赠科研通 3266932
什么是DOI,文献DOI怎么找? 1803614
邀请新用户注册赠送积分活动 880989
科研通“疑难数据库(出版商)”最低求助积分说明 808527